Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
BMC Nephrol ; 21(1): 410, 2020 09 23.
Artículo en Inglés | MEDLINE | ID: mdl-32967631

RESUMEN

BACKGROUND: Concurrent type 1 diabetes mellitus (T1DM) and idiopathic nephrotic syndrome is rare, and most previously reported cases were in children. We report the case of an adult woman who developed T1DM and minimal change nephrotic syndrome (MCNS) nearly simultaneously. CASE PRESENTATION: A 24-year-old woman had first presented to another hospital with nausea, vomiting, and fatigue. She was diagnosed with diabetic ketoacidosis and T1DM on the basis of her hyperglycemia, ketoacidosis, and positive anti-glutamic acid decarboxylase antibody test result. Rapid infusion of normal saline and insulin administration alleviated hyperglycemia and ketoacidosis. Two weeks after admission, however, she developed nephrotic syndrome (NS) with rapidly decreasing urine volume. She was referred to our hospital with a diagnosis of acute kidney injury. Although she temporarily required dialysis and high doses of insulin, within 1 month NS and acute kidney injury had been alleviated by oral prednisolone and low-density lipoprotein apheresis. Renal biopsy showed minor glomerular abnormalities without diabetic nephropathy, so we diagnosed her with MCNS. Seven weeks after the discharge, NS relapsed, and cyclosporine was added to prednisolone. However, NS relapsed twice within the next 4 months, so we started her on rituximab. At 6 months after initiating rituximab therapy, she remained in complete remission. Her mother also had T1DM but not MCNS. The patient had HLA-DRB1*09:01/09:01, DQB1*03:03/03:03, and her mother had HLA-DRB1*04:05/09:01, DQB1*03:03/04:01. CONCLUSIONS: Concurrent T1DM and MCNS is rare and their coexistence might be coincidental. Alternatively, they might have been caused by an underlying, unidentified genetic predisposition. Previous reports and our patient's findings suggest that specific HLA alleles and haplotypes or a Th1/Th2 imbalance might be associated with T1DM and MCNS that occurred nearly simultaneously.


Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Nefrosis Lipoidea/complicaciones , Adulto , Biopsia , Análisis Químico de la Sangre , Eliminación de Componentes Sanguíneos , Niño , Preescolar , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Femenino , Glucocorticoides/uso terapéutico , Humanos , Hipoglucemiantes/uso terapéutico , Lactante , Recién Nacido , Insulina/uso terapéutico , Japón , Glomérulos Renales/patología , Nefrosis Lipoidea/patología , Nefrosis Lipoidea/terapia , Prednisolona/uso terapéutico , Diálisis Renal
2.
Clin Nephrol ; 93(6): 300-305, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32213283

RESUMEN

An elderly Japanese woman with bilateral renal artery occlusion who developed massive proteinuria after unilateral percutaneous transluminal renal angioplasty (PTRA) is reported. She had a history of percutaneous coronary intervention and subsequently developed refractory hypertension. She was diagnosed with renovascular hypertension caused by bilateral total occlusion of the renal arteries, and underwent PTRA for the left renal artery. Nephrotic-range proteinuria from the left kidney, confirmed by split urine collection from each kidney under cytoscopic examination, and low-grade fever with positive C-reactive protein became obvious after PTRA. Giant cell arteritis (GCA) was also diagnosed by positive findings on fluorodeoxyglucose-positron emission tomography in the common carotid arteries, subclavian arteries, and aorta, but not in the renal arteries. Administration of corticosteroid and angiotensin-converting enzyme inhibitor decreased the proteinuria (> 9 - 2 g/day). Possible mechanisms for the development of nephrotic-range proteinuria and a hypothesis that GCA became obvious after PTRA are discussed.
.


Asunto(s)
Angioplastia/efectos adversos , Arteritis de Células Gigantes/etiología , Síndrome Nefrótico/etiología , Obstrucción de la Arteria Renal/cirugía , Anciano , Femenino , Humanos , Hipertensión Renovascular/etiología , Proteinuria/etiología , Obstrucción de la Arteria Renal/complicaciones
3.
F1000Res ; 9: 969, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-34868569

RESUMEN

Basal ganglia lesions showing an expansile high signal intensity on T2-weighted MRI are termed the lentiform fork sign. This specific finding is mainly observed in diabetic patients with uremic encephalopathy with metabolic acidosis, although there are also reports in patients with ketoacidosis, dialysis disequilibrium syndrome, intoxication, and following drug treatment (e.g., metformin). A 57-year-old Japanese man on chronic hemodialysis for 4 years because of diabetic nephropathy was admitted to our hospital for relatively rapid-onset gait disturbance, severe dysarthria, and consciousness disturbance. Brain T2-weighted MRI showed the lentiform fork sign. Hemodialysis was performed the day before admission, and laboratory tests showed mild metabolic (lactic) acidosis, but no uremia. Surprisingly, metformin, which is contraindicated for patients with end-stage kidney disease, had been prescribed for 6 months in his medication record, and his sluggish speaking and dysarthria appeared gradually after metformin treatment was started. Thus, the encephalopathy was considered to be related to metformin treatment. He received hemodialysis treatment for 6 consecutive days, and his consciousness disturbance and dysarthria improved in 1 week. At the 8-month follow-up, the size of the hyperintensity area on MRI had decreased, while the mild gait disturbance remained. Considering the rapid onset of gait and consciousness disturbance immediately before admission, diabetic uremic syndrome may also have occurred with metformin-related encephalopathy, and resulted in the lentiform fork sign, despite the patient showing no evidence of severe uremia on laboratory data.


Asunto(s)
Encefalopatías , Diabetes Mellitus , Nefropatías Diabéticas , Uremia , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/terapia , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Diálisis Renal , Uremia/complicaciones , Uremia/terapia
4.
CEN Case Rep ; 9(1): 74-80, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31863345

RESUMEN

Noninflammatory necrotizing vasculopathy, also referred to as lupus vasculopathy, is not infrequently observed in the pathology of lupus nephritis. It affects vessels causing them to become severely narrowed and occluded by a mechanism involving immune complexes. We experienced a 51-year-old woman with lupus nephritis class IV + V, which was accompanied by lupus vasculopathy. Renal biopsy and light microscopy showed eosinophilic hyaline-like material in the afferent and/or efferent arterioles, which narrowed the lumen, and which were positive for IgG by immunofluorescent analysis. Electron microscopy indicated that amorphous material and endothelial detachment occluded the arterioles. These findings were consistent with those of lupus vasculopathy. We treated the patient with steroids and cyclophosphamide. By the day of discharge, her levels of creatinine and proteinuria had undergone partial remission. Although lupus vasculopathy was implied as a lesion with unfavorable renal prognosis, some recent reports suggest its true renal prognosis is not unfavorable necessarily. Nevertheless, lupus vasculopathy is an important finding in diagnosis in contradiction to other vascular legions in systemic lupus erythematosus. In addition, a standard therapy has also not been established. Therefore, it is important to accumulate cases of lupus vasculopathy to determine its prognosis and develop standard treatments.


Asunto(s)
Arteriolas/lesiones , Riñón/irrigación sanguínea , Nefritis Lúpica/complicaciones , Enfermedades Vasculares/etiología , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Arteriolas/patología , Biopsia , Creatinina/sangre , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Quimioterapia Combinada , Técnica del Anticuerpo Fluorescente/métodos , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Riñón/patología , Nefritis Lúpica/diagnóstico , Nefritis Lúpica/inmunología , Nefritis Lúpica/patología , Microscopía Electrónica/métodos , Persona de Mediana Edad , Pronóstico , Proteinuria/orina , Enfermedades Vasculares/tratamiento farmacológico , Enfermedades Vasculares/patología
5.
Sci Rep ; 9(1): 6630, 2019 04 29.
Artículo en Inglés | MEDLINE | ID: mdl-31036872

RESUMEN

Characterisation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in chronic haemodialysis patients and its prognostic significance in age stratification have not been addressed. A prospective cohort study with cross-sectional analyses at baseline was performed. Outcomes were all-cause mortality, non-malignancy-related mortality, and cardiovascular disease (CVD)-related mortality. NT-proBNP was significantly higher in elderly, female, and low dry weight patients. Study patients were divided into two groups: Group-O (≥75 years) and Group-Y (<75 years). The 7-year follow-up receiver operating curve analysis showed that NT-proBNP significantly predicted all outcomes. All-cause mortality cut-off points were significantly different among the groups (total cohort, 5375 pg/mL; Group-Y, 3682 pg/mL; Group-O, 11750 pg/mL). Cox regression analysis showed risks for all outcomes by tertile NT-proBNP significantly higher in the total cohort and Group-Y as adjusted by potential confounders. For all-cause mortality, hazard ratios and 95% confidence intervals (CI) were T2 1.70 (0.89 to 3.25), p = 0.11, T3 2.95 (1.54 to 5.67), p < 0.01 in Group-Y; and T2 1.00 (0.64 to 1.58), p = 1.00; T3 1.50 (0.94 to 2.40), p = 0.09 in Group-O. In conclusion, NT-proBNP was significantly higher in elderly, female, and low dry weight chronic dialysis patients. NT-proBNP was significantly associated with all outcomes. However, this association was reduced in elderly patients.


Asunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Péptido Natriurético Encefálico/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Anciano , Enfermedades Cardiovasculares/mortalidad , Intervalos de Confianza , Estudios Transversales , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Curva ROC , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...